Progress and introduction
of main products
LQ041, a long half-life IL-5 antagonist, had a very significant eosinophil inhibition effect, which is 100 times the activity of Nucala. At the same time, LQ041 is a fusion protein with modified Fc segment, which has a longer half-life in vivo compared with conventional Fc. With good efficacy and half-life, LQ041 expected to be administered once every 4-6 months in clinical application, which makes LQ041 better complianced. In addition, LQ041 has good stability and solubility, which is conducive to the development of small volume subcutaneous drug delivery.
Good stability
High pulmonary drug concentrations
Minimal systemic adverse effects
Produced by Pichia pastoris at high yield, lower cost
The pathogenesis of asthma involves multiple inflammatory pathways, and eosinophils play an important role in the pathogenesis of asthma. IL-5 can promote the differentiation and maturation of eosinophils, and plays a key role in the pathogenesis of eosinophil asthma. Therefore, IL-5 has been a suitable target for asthma treatment, and is highly expected for the treatment of refractory and glucocorticoid-resistant asthma. Many studies have shown that blocking the IL5/IL5R signal pathway can effectively inhibit the maturation and differentiation of eosinophils, thus effectively controlling the inflammatory diseases caused by eosinophils.
EOS asthma, HES, EGPA
Subcutaneous injection
Partial toxicity studies completed.
